GAMMA Investing LLC Boosts Stock Position in Grifols, S.A. (NASDAQ:GRFS)

GAMMA Investing LLC lifted its position in Grifols, S.A. (NASDAQ:GRFS) by 426.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 26,087 shares of the biotechnology company’s stock after buying an additional 21,128 shares during the quarter. GAMMA Investing LLC’s holdings in Grifols were worth $1,850,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of GRFS. Soleus Capital Management L.P. boosted its position in shares of Grifols by 46.1% during the 4th quarter. Soleus Capital Management L.P. now owns 6,605,425 shares of the biotechnology company’s stock worth $49,144,000 after acquiring an additional 2,083,722 shares in the last quarter. Norges Bank acquired a new position in shares of Grifols during the 4th quarter worth about $14,434,000. Credit Industriel ET Commercial acquired a new position in shares of Grifols during the 4th quarter worth about $4,537,000. Brandes Investment Partners LP boosted its position in shares of Grifols by 3.0% during the 4th quarter. Brandes Investment Partners LP now owns 20,496,093 shares of the biotechnology company’s stock worth $152,491,000 after acquiring an additional 592,096 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of Grifols by 11.9% during the 4th quarter. Janus Henderson Group PLC now owns 3,045,260 shares of the biotechnology company’s stock worth $22,642,000 after acquiring an additional 324,869 shares in the last quarter.

Grifols Stock Down 1.2%

Shares of NASDAQ GRFS opened at $8.87 on Friday. The stock has a market cap of $6.10 billion, a PE ratio of 7.58 and a beta of 0.53. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a 52-week low of $5.79 and a 52-week high of $9.96. The business has a 50-day moving average price of $7.69 and a 200 day moving average price of $7.56.

Analyst Ratings Changes

Separately, Wall Street Zen raised Grifols from a “hold” rating to a “buy” rating in a research report on Friday, May 23rd.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.